These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31941074)

  • 1. Synthesis of Tilmicosin Nanostructured Lipid Carriers for Improved Oral Delivery in Broilers: Physiochemical Characterization and Cellular Permeation.
    Sahito B; Zhang Q; Yang H; Peng L; Gao X; Kashif J; Ul Aabdin Z; Jiang S; Wang L; Guo D
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31941074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.
    Zhang Q; Yang H; Sahito B; Li X; Peng L; Gao X; Ji H; Wang L; Jiang S; Guo D
    Colloids Surf B Biointerfaces; 2020 Mar; 187():110649. PubMed ID: 31767412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Tilmicosin-Loaded Nanostructured Lipid Carriers Using Orthogonal Design for Overcoming Oral Administration Obstacle.
    Wen J; Gao X; Zhang Q; Sahito B; Si H; Li G; Ding Q; Wu W; Nepovimova E; Jiang S; Wang L; Kuca K; Guo D
    Pharmaceutics; 2021 Feb; 13(3):. PubMed ID: 33669090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
    Dudhipala N; Janga KY; Gorre T
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.
    Yu Q; Hu X; Ma Y; Xie Y; Lu Y; Qi J; Xiang L; Li F; Wu W
    Drug Deliv; 2016 May; 23(4):1469-75. PubMed ID: 27187522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
    Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
    Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
    J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
    Li H; Chen M; Su Z; Sun M; Ping Q
    Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide.
    Zhang T; Chen J; Zhang Y; Shen Q; Pan W
    Eur J Pharm Sci; 2011 Jun; 43(3):174-9. PubMed ID: 21530654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
    Banerjee S; Pillai J
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
    [No Abstract]   [Full Text] [Related]  

  • 11. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution.
    Beloqui A; Solinís MÁ; Delgado A; Evora C; Isla A; Rodríguez-Gascón A
    J Microencapsul; 2014; 31(1):1-8. PubMed ID: 23631381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanostructured lipid carriers for oral delivery of silymarin: Improving its absorption and in vivo efficacy in type 2 diabetes and metabolic syndrome model.
    Piazzini V; Micheli L; Luceri C; D'Ambrosio M; Cinci L; Ghelardini C; Bilia AR; Di Cesare Mannelli L; Bergonzi MC
    Int J Pharm; 2019 Dec; 572():118838. PubMed ID: 31715362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanostructured lipid carriers (NLCs) for drug delivery and targeting.
    Fang CL; Al-Suwayeh SA; Fang JY
    Recent Pat Nanotechnol; 2013 Jan; 7(1):41-55. PubMed ID: 22946628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
    Chen CC; Tsai TH; Huang ZR; Fang JY
    Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to enhance oral delivery of amphotericin B: a comparison of uncoated and enteric-coated nanostructured lipid carriers.
    Nimtrakul P; Sermsappasuk P; Tiyaboonchai W
    Drug Deliv; 2020 Dec; 27(1):1054-1062. PubMed ID: 32633144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery.
    Gao X; Zhang J; Xu Q; Huang Z; Wang Y; Shen Q
    Drug Dev Ind Pharm; 2017 Apr; 43(4):661-667. PubMed ID: 28043185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
    Wang W; Chen L; Huang X; Shao A
    AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers.
    Jawahar N; Hingarh PK; Arun R; Selvaraj J; Anbarasan A; S S; G N
    Int J Biol Macromol; 2018 Apr; 110():269-275. PubMed ID: 29402457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
    Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
    Singh A; Neupane YR; Mangla B; Kohli K
    J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.